Ischaemic and valvular heart disease

Ischaemic and valvular heart disease Ischaemic and valvular heart diseases are two major categories of cardiovascular disorders that significantly impact global health. While they involve different pathological mechanisms, both contribute substantially to morbidity and mortality worldwide. Understanding their differences, causes, and management strategies is essential for clinicians and patients alike.

Ischaemic and valvular heart disease Ischaemic heart disease (IHD), also known as coronary artery disease, primarily results from reduced blood flow to the myocardium due to atherosclerosis of the coronary arteries. This narrowing limits oxygen and nutrient delivery, especially during increased cardiac demand, leading to chest pain or angina. In severe cases, it can cause myocardial infarction (heart attack), where part of the heart muscle is irreversibly damaged. Risk factors for IHD include hypertension, hyperlipidemia, smoking, diabetes, obesity, and a family history of cardiovascular disease. The pathophysiology involves the buildup of fatty plaques within the arterial walls, which can rupture and cause thrombus formation, further obstructing blood flow.

Ischaemic and valvular heart disease Diagnosis of ischaemic heart disease typically involves clinical assessment, electrocardiograms (ECGs), stress testing, and imaging modalities such as coronary angiography. Management aims to restore and maintain adequate blood flow to the heart muscle, involving lifestyle modifications, pharmacotherapy (like antiplatelet agents, statins, beta-blockers), and invasive procedures such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Preventing progression and managing symptoms are central to improving patient outcomes.

Valvular heart disease (VHD), on the other hand, involves abnormalities in one or more of the heart valves—mitral, aortic, tricuspid, or pulmonary valves—that interfere with normal blood flow through the heart. Valvular disorders can be congenital or acquired. Common causes include rheumatic fever (leading to rheumatic valvular disease), degenerative calcification (especially of the aortic and mitral valves in the elderly), infective endocarditis, and connective tissue disorders like Marfan syndrome. Ischaemic and valvular heart disease

Ischaemic and valvular heart disease The clinical presentation varies depending on the valve affected and the severity of dysfunction. Patients may experience symptoms such as breathlessness, fatigue, palpitations, or heart failure signs. Diagnosis involves echocardiography to assess valve structure, function, and the degree of stenosis or regurgitation. Management strategies depend on severity; mild cases often require monitoring, while significant stenosis or regurgitation may necessitate surgical intervention, including valve repair or replacement. Medical therapy can include diuretics, vasodilators, or anticoagulants, particularly in atrial fibrillation associated with valvular disease.

Both ischaemic and valvular heart diseases can coexist, complicating treatment and prognosis. A comprehensive approach involves managing risk factors, optimizing medical therapy, and considering surgical options when indicated. Advances in minimally invasive techniques, improved imaging, and better understanding of disease mechanisms continue to enhance outcomes for affected patients. Ischaemic and valvular heart disease

In conclusion, while ischaemic and valvular heart diseases differ in their origins and pathophysiology, they are interconnected in their impact on cardiac function. Early detection, effective management, and lifestyle alterations remain pivotal in reducing their burden and improving quality of life for patients.